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• Expression of VNN2
identifies B-cell precur-
sor ALL cases with in-
creased resistance to
chemotherapy.
• VNN2 positivity occurs
across different geno-




Most relapses of acute lymphoblastic leukemia (ALL) occur in patients with a medium risk
(MR) for relapse on theAssociazione Italianadi Ematologia eOncologia Pediatrica andBerlin-
Frankfurt-Münster (AIEOP-BFM) ALL protocol, based on persistence of minimal residual
disease (MRD). New insights into biological features that are associated with MRD are
needed. Here, we identify the glycosylphosphatidylinositol-anchored cell surface protein
vanin-2 (VNN2; GPI-80) by charting the cell surface proteome of MRD very high-risk (HR)
B-cell precursor (BCP) ALL using a chemoproteomics strategy. The correlation between
VNN2 transcript and surface protein expression enabled a retrospective analysis (ALL-BFM
2000; N5 770 cases) using quantitative polymerase chain reaction to confirm the association
of VNN2 with MRD and independent prediction of worse outcome. Using flow cytometry, we
detected VNN2 expression in 2 waves, in human adult bone marrow stem and progenitor
cells and in the mature myeloid compartment, in line with proposed roles for fetal
hematopoietic stem cells and inflammation. Prospective validation by flow cytometry in the
ongoing clinical trial (AIEOP-BFM 2009) identified 10% (103/1069) of VNN21 BCP ALL
patients at first diagnosis, primarily in the MRD MR (48/103, 47%) and HR (37/103, 36%)
groups, across various cytogenetic subtypes. We also detected frequent mutations in
epigenetic regulators in VNN21 ALLs, including histone H3 methyltransferases MLL2,
SETD2, and EZH2 and demethylase KDM6A. Inactivation of the VNN2 gene did not impair
leukemia repopulation capacity in xenografts. Taken together, VNN2 marks a cellular state
of increased resistance to chemotherapy that warrants further investigations. Therefore,
this marker should be included in diagnostic flow cytometry panels.
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Despite the remarkable improvements in molecular classification,1 our
understanding of the factors associated with treatment resistance
remains scarce. Thus far, assessment of minimal residual disease
(MRD) remains 1 of the most important parameters for risk stratification
in acute lymphoblastic leukemia (ALL).2 More recently, improved
classifiers were proposed based on the combination of cytogenetic
information and MRD. Such a score can help to classify patients with
a very low risk for relapse,3,4 providing a rationale to decrease
treatment intensity. Markers to identify patients at very high risk (VHR)
for relapse have been defined for rare subgroups, such as TCF3-HLF1
ALL,5 hypodiploid ALL,6 or KMT2A (MLL) rearrangements.7 On the
Associazione Italiana di Ematologia e Oncologia Pediatrica and Berlin-
Frankfurt-Münster (AIEOP-BFM) ALL 2009 treatment protocol,2 the
majority of relapses occur in the group of patients who are at medium
risk (MR) by MRD. Recently, a subgroup with very poor outcome
has been identified with deletions in IKAROS, together with other
mutations (IKZF1plus).8 The significance of BCR-ABL–like mutations in
tyrosine kinase genes9 for VHR for relapse classification remains to be
clarified, because precise information from next-generation sequenc-
ing is emerging.1 Clearly, more efforts are needed to improve our
understanding and molecular classification of resistant disease.
Mapping the leukemic cell surface more precisely will be relevant in
the era of antigen receptor–directed immunotherapy. Using the chemo
proteomics cell surface capturing (CSC) technology to phenotype
cells without antibodies, a bird’s eye view of the repertoire of expressed
cell surface proteins and their relative abundance (“surfaceome”) can
be determined in development10 and disease.11,12 Here, we report
about surfaceome proteins that are differentially present on leukemia
cells with increased resistance to conventional treatment in ALL
compared with good-risk ALL and identify an association between the
glycosylphosphatidylinositol (GPI)-anchored surface protein vanin-2
(VNN2; GPI-80) and MRD in the AIEOP-BFM ALL 2009 study. The
human vanin gene family consists of VNN1, VNN2, and VNN3,
whereas in mice, only Vnn1 and Vnn3 orthologs have been identified.13
Human VNN1 and VNN2 are membrane-associated proteins, whereas
VNN3 lacks GPI anchoring and is secreted.14 The function of the vanin
family remains to be explored. VNN1 has pantetheinase activity to
generate pantothenic acid and cysteamine, activating stress pathways
and inflammation by inhibition of gluthatione.14,15 Additionally, VNN1 is
involved in the thymus homing of immature T lymphocytes in mice.16
VNN2 is mainly expressed in the hematopoietic system on myeloid
cells and, to a lesser extent, on lymphoid cells, contributing to leukocyte
adhesion and migration to inflammatory sites.17 Recently, VNN2 has
been implicated as a human fetal liver hematopoietic stem cell
(FLHSC) marker, identifying a subset of FLHSCs in xenotransplanta-
tion assays,18 as well as a marker of CD342 human cord blood–
derived primitive hematopoietic stem cells (HSCs).19 Our study
establishes the association between VNN2 and drug resistance




Patient specimens were included for the retrospective analysis of
patients who were enrolled on the ALL-FM 2000 trial (NCT00430118)
between June 1999 and December 2004, according to availability in
the central biological specimen bank (supplemental Figure 1A).
The characteristics of this cohort are provided in Table 1.20 The
prospective analysis was performed by the reference laboratories of
the AIEOP-BFM ALL 2009 (NCT01117441) for patients enrolled
between 2009 and 2018. Relapse samples were available from
patients included in the BFM relapse trial 2002 (ALL-REZ BFM
2002; NCT00114348). Informed consent, in accordance with the
Declaration of Helsinki, was obtained for all patients. Patients were
classified as standard risk (SR), MR, or high risk (HR) for relapse,
according to the clinical criteria used in the ALL-BFM 2000
trial.21,22 Briefly, HR patients are those presenting with 1 of the
following features: poor response to prednisone, no complete
remission at the end of induction on day 33, MRD$1 3 1023 after
consolidation at time point 2 (day 78), or KMT2A-AFF1 positivity.
SR patients are MRD negative at the end of induction (day 33) and
after consolidation (day 78), with $2 markers with a sensitivity of
1024 and no HR criteria. All other patients were classified as MR.
Identification of proteins that are preferentially
expressed in HR ALL
To select proteins preferentially identified in HR ALL, we used
a proteomics dataset that was obtained using CSC technology, as
previously reported.12 To identify the ALL surfaceome proteotype,
cell surface residing glycoproteins were chemically tagged on living
cells and subsequently analyzed by data-dependent acquisition
mass spectrometry.12 A comparable number of peptides that were
matched to proteins were identified in VHR and SR patients, with
an average 5481 peptides in SR ALL and 5714 peptides in VHR
ALL. Data from Mirkowska et al12 are included in supplemental
Table 1. To identify candidates of the cell surface proteome that are
expressed more often at the surface of 8 HR ALL samples
compared with the 11 SR ALL samples in that dataset, we filtered
for proteins that are identified in $50% of all HR cases ($4/8
samples) and not more than 30% of SR cases (#3 samples).
Immunophenotyping
Immunophenotyping was done in the corresponding BFM centers,
and data were generated using the stringent diagnostic standards
developed and approved by the AIEOP-BFM ALL FLOW-SG,23
which are based on 2016 World Health Organization criteria, the
EGIL classification, and the Bethesda 2006 recommendations.
Validation of VNN2 antibodies by flow cytometry and
definition of VNN2 positivity
We tested 2 commercial monoclonal VNN2 antibodies: 1 that was
generated with recombinant human VNN2 (clone 04) and another
that was generated with extracts from neutrophils (clone 3H9). We
stained 3 human leukemia samples and observed a stronger signal
with the 3H9 clone (supplemental Figure 1B). We further validated
this clone by staining peripheral blood (PB) cells from a healthy
adult donor (supplemental Figure 1C) and by generating lentiviral
VNN2-knockout patient-derived xenograft (PDX) cells and VNN2-
overexpressing cells (supplemental Figure 1D).
To define positivity in patient samples, the internal cross-lineage
CD45bright lymphocyte population for each sample was used
to set the VNN2 gate. The frequency of VNN2 positivity was
evaluated based on the standard operating procedure of AIEOP-
BFM ALL Immunophenotyping Consensus Guidelines.23 A frequency
of VNN21 cells $10% of control was considered positive for VNN2.
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To define positivity in xenograft samples, we used a fluorescence-
minus-one control, which consisted of a sample stained with all
antibodies except VNN2. VNN2 staining always detected a homo-
geneous population with increased fluorescence compared with
in-sample control lymphocyte populations.
Quantitative polymerase chain reaction
Total RNA was isolated with TRIzol reagent and subsequently
extracted with an RNeasy Mini Kit (cat. no, 74106; Qiagen),
according to standardized protocols. The amount and quality of the
extracted RNA were measured with a spectrophotometer (Nano-
drop ND-1000) and a Bioanalyzer.
TaqMan Gene Expression Assays were used to measure messen-
ger RNA (mRNA) abundance of VNN2, with SDHA as control gene.
TaqMan Gene Expression Master Mix (cat. no. 4369016; Applied
Biosystems, Foster City, CA), Assay-On-Demand (TaqMan Gene
Expression Assays, Hs01546812_m1 VNN1, Hs00190581_m1
VNN2, Hs00417200_m1 SDHA; Applied Biosystems), and water
were mixed (5:3:2), and complementary DNA (1:3 dilution) was
added. The same was done using a SYBR Green assay for VNN2
and SDHA as control gene (QuantiTect SYBR Green PCR Kit,
Power SYBR Green PCR Master Mix, cat. no. 4367659, Applied
Biosystems; Quantitect Primer Assay, Hs_VNN2_1_SG, cat. no.
QT00034902 and Hs_SDHA_1_SG, cat. no. QT00059486,
Qiagen).
A 7900HT Fast Real-Time PCR System (Applied Biosystems) was
used for both methods. We used the following cycles: 2 minutes
50°C, 10 minutes 95°C, 503 (10 seconds 95°C/1 minute 60°C).
Analysis was performed with SDS 2.2 software using the 2-DCT
value.
Statistics
VNN2 threshold was defined based on SYBR Green PCR values,
which divided a group of 770 patients from the ALL-BFM 2000
study into a training set (one third of the patients) and a test set
(two thirds of the patients). The VNN2 threshold associated with
a higher risk for relapse was defined based on the lowest P value in
a univariate Cox model in the training set. This threshold was used
for dichotomizing the patients in the test set. Samples with 2-DDCT
. 1.13 (cutoff VNN2 transcript level) were tested by flow cytometry
Table 1. Clinical features of VNN2
1
patients





VNN2 Negative Positive Positive
615 (79.8) 155 (20.1) 72 (—)
Age at diagnosis, y
1-10 456 (74.1) 101 (65.1) 41 (57.9) 557 (72.3) 3099 (74.6)
$10 159 (25.8) 54 (34.8) 31 (43.0) 213 (27.6) 1053 (25.4)
WBC count, 3109/L
,50 458 (74.4) 89 (57.4) 52 (72.2) 547 (71.0) 3351 (80.7)
50-100 74 (12.0) 28 (16.1) 5 (6.9) 102 (13.2) 383 (9.2)
$100 83 (13.4) 38 (24.5) 3 (4.1) 121 (15.7) 403 (9.7)
CNS status
Negative (1) 518 (84.2) 134 (86.4) 53 (73.6) 712 (92.5) 3757 (90.7)
Positive (2, 3) 22 (3.5) 10 (6.4) 12 (16.6) 32 (4.1) 142 (3.4)
Risk (MRD)
SR 209 (33.9) 32 (20.6) 18 (25.0) 241 (31.2) 1341 (32.3)
MR 268 (43.5) 78 (50.3) 4 (66.6) 346 (44.9) 1779 (42.8)
HR 30 (4.9) 14 (9.0) 37 (51.4) 44 (5.7) 146 (5.9)
TEL-AML1
Negative 434 (70.6) 135 (87.7) 69 (95.8) 569 (73.8) 3019 (74)
Positive 160 (26.0) 16 (10.3) 3 (4.1) 176 (22.8) 868 (20.9)
KMT2A
Negative 612 (99.5) 152 (99.5) 71 (99) 764 (99.2) 4130 (99.5)
Positive 3 (0.2) 3 (0.2) 1 (1.3) 3 (0.5) 6 (0.8)
CRLF2 aberrations
Immunoglobulin H fusion 4 (0.6) — (—) 1 (1.3) 4 (0.7) 4 (0.5)
P2RY8 fusion 16 (2.6) 3.2 (—) — (—) 21 (2.7) 21 (2.7)
3X CRLF2 20 (3.2) 4 (2.5) — (—) 24 (3.1) 24 (3.1)
All data are n (%).
—, no sample of the corresponding genetic group observed; WBC, white blood cell.
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(FCM) based on sample availability. Event-free survival was defined
as the time from diagnosis to the date of last follow-up or first event.
Events were nonresponse, relapse, secondary neoplasm, or death
from any cause. Failure to achieve remission due to death before
complete remission or nonresponse was considered as event at
time 0. The Kaplan-Meier method was used to estimate survival
rates; differences between groups were compared with the log-
rank test. Cumulative incidence functions for competing events
were constructed using the method of Kalbfleisch and Prentice and
were compared with Gray’s test.24 Statistical analysis was done
using GraphPad Prism version 8.0 (GraphPad Software). The
prognostic value of VNN2 was analyzed with a Cox regression
model including covariates that are known to be risk factors in the
ALL-BFM 2000 study and used as covariates in another study8:
ETV6-RUNX1 positivity, poor prednisone response, white blood cell
count$1003 103/mL, MRD low risk, MRD HR, and MRD slow early
response. Statistical analysis was done using GraphPad Prism 8
(GraphPad software) and SAS 9.4 (SAS Institute, Cary, NC).
Results
A set of proteins implicated in cell adhesion and
immune response is preferentially present on the
surface of MRD1 leukemia
To identify cell surface markers that are characteristic of resistant
disease, we interrogated the cell surface proteomes of 19 B-cell
precursor (BCP) ALL PDXs previously acquired using CSC
technology.12 This dataset included specimens from 8 patients with
VHR ALL, as defined by persistence of MRD (.5 3 1024) after
induction chemotherapy, consolidation therapy, and 3 highly
intensive postconsolidation blocks according to the ALL-BFM
2000 protocol,21,25,26 and 11 patients with an excellent clinical
outcome (SR ALL). We identified 13 proteins that were detected
more frequently in VHR ALL (Table 2), including several surface
proteins that are involved in cell adhesion and migration: the GPI-
anchored vanin family of proteins (VNN1 and VNN2 [GPI-80]), with
VNN2 being exclusively detected on the cell surface of VHR
ALL cases, the immunoglobulin-like CEA family member CEAM1,
the C-type lectin receptor CD302, and the sialic acid binding
immunoglobulin-like lectin CD33, as well as ITGAM (CD11b), which
is a subunit of the complement receptor 3 and has been linked to
chemotherapy resistance in ALL.27 Furthermore, the receptors for
activated complement CR1 and CR2, as well as components of
prosurvival signaling pathways (TNFR1B, IGF1R), were detected in
VHR ALL cases.
The GPI-anchored surface protein VNN2 is associated
with MRD and a higher risk for relapse
Given that VNN2 is implicated in early immature compartments and
that we identified 2 members of the same vanin protein family in our
experiment, we next focused on the validation of VNN2 in ALL. To
explore retrospective banked samples, we first established a corre-
lation between VNN2 RNA and protein expression in 34 PDXs
derived from HR, MR, and SR patients based on their MRD after
induction chemotherapy (Figure 1A). Detection of VNN2 by FCM
correlated with detection of VNN2 mRNA by quantitative PCR
(q-PCR) (Figure 1A). VNN2 was detected preferentially on the
surface of leukemia cells from patients with MR ALL and HR ALL.
We compared VNN2 expression by FCM on matched samples from
11 patients from diagnosis, relapse, and PDX to verify that VNN2
expression is maintained during disease evolution and in PDXs
(supplemental Table 2). Thus PDXs constitute an acceptable model
to study this phenotype. We then performed a retrospective
quantitative RT-PCR analysis on banked RNA from 770 pediatric
Table 2. Proteins identified in MRD VHR ALL by CSC
SR VHR
01 02 03 04 05 06 07 14 15 16 17 08 09 10 11 12 13 18 19
Adhesion and migration
VNN2 1 1 1 1
VNN1 1 1 1 1 1 1 1 1
ITGAM 1 1 1 1 1 1
CD33 1 1 1 1 1
CD302 1 1 1 1 1
CEAM1 1 1 1 1
Signaling
TNR1B 1 1 1 1 1
IGF1R 1 1 1 1 1 1 1 1 1 1 1
Immune response
CR1 1 1 1 1 1
CR2 1 1 1 1 1 1 1
Others
SORL 1 1 1 1 1
2B19 1 1 1 1 1 1 1
GI24 1 1 1 1 1 1 1 1 1
1, detected by CSC as described in Mirkowska et al.12
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Figure 1. VNN2 expression is associated with an increased risk for relapse in BCP ALL. (A) VNN2 mRNA expression by q-PCR correlates with detection of VNN2 at
the cell surface by FCM. PDXs from patients included in the ALL-BFM-2000 study were used for correlation. The percentage of VNN21 cells by FCM with respect to the
fluorescence-minus-one control is plotted on the y-axis against the mRNA levels by q-PCR as logarithmic value of 2-DCT (DCT 5 CTVNN2 2 CTSDHA) on the x-axis. MRD-based
risk stratification in ALL-BFM-2000 is indicated as SR, eMR, and HR. Patients with the translocation t(17;19) leading to TCF3-HLF are highlighted as TCF3-HLF1. (B) Five-
year pEFS (upper part of the panel) and probability of cumulative incidence of relapse (pCIR; lower part of the panel) of 476 patients (test set) treated on the ALL-BFM 2000
study stratified according to VNN2 positivity by q-PCR. The cutoff for positivity was set to 1.13 DCT, as described in Materials and methods. (C-E) Five-year pEFS (upper part
of the panel) and pCIR (lower part of the panel) of the same 476 patients in a subgroup analysis based on their risk stratification [SR (C), MR (D), and HR (E) for relapse] in
the ALL-BFM-2000 study. A statistically significant difference was observed for pEFS and pCIR in VNN21 vs VNN22 patients in the MR group (P , .01). (F) Retrospective
analysis of VNN2 expression by FCM on available archived samples from VNN21 ALL patients based on q-PCR. Sample selection is described in supplemental Figure 1.
Twenty-two of 40 positive samples by q-PCR were confirmed VNN21 by FCM. Cutoff for VNN2 positivity by FCM . 10% (Materials and methods). pEFS of 22 VNN21
patients based on FCM is plotted in comparison with pEFS of 615 VNN22 patients based on q-PCR from the total retrospective cohort. P , .0001, log-rank test.
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ALL patients treated on the ALL-BFM-2000 protocol (Table 1).
Using 294 (38%) of 770 patients as a training set, we established
a cutoff (q-PCR value$1.13) to determine the association between
risk and VNN21 samples (see Materials and methods) and explored
the correlation between VNN2 positivity and outcome in a test set
of the remaining 476 patients with BCP ALL (Figure 1B-E;
supplemental Figure 1A). In total, 155 of 770 patients had VNN2
expression $ 1.13. The 5-year probability of event-free survival
(pEFS) was inferior in VNN21 patients (0.87; standard error, 0.02
for VNN2 ,1.13 and 0.67; standard error, 0.05 for VNN2 $1.13;
P , .0001) (Figure 1B). We detected a significant increase in
relapses, predominantly in the MR ALL subgroup (P 5 .0003)
(Figure 1D). In the HR group, the increased incidence of relapse for
VNN21 patients was not significant, which may be explained by the
comparable state of drug resistance in other subtypes of the HR
cohort or the fact that some VNN21 patients may benefit from
HR treatment intensification, including stem cell transplantation
(Figure 1E). Thus, further exploration of this phenotype may be most
relevant for the MR group, for which new markers to improve risk
stratification are warranted. Importantly, using a Cox regression
analysis, VNN2 was found to be an independent prognostic factor
compared with MRD and other clinical factors (Table 3). We also
noticed a higher proportion of central nervous system (CNS)
involvement in VNN21 patients (6.4% in the retrospective cohort,
16% in the prospective cohort) compared with the frequency of
CNS1 patients in the ALL-BFM-2000 cohort (3.4% CNS1; Tables
2 and 3).
For these retrospective analyses, biobanked material with bone
marrow (BM) involvement .80% was selected. Because VNN2 is
expressed in the normal myeloid compartment, residual myeloid
cells may express higher levels of VNN2 and, thus, generate
a background signal in the entire cohort. Given the strong
correlation between RNA and FCM data, we propose to use FCM
to determine VNN2 expression at the single-cell level in prospective
studies. To gather pilot information, we used 40 of 155 VNN21
samples for which viably frozen specimens were available from the
biobanks and confirmed VNN2 by FCM in 22 of 40 (supplemental
Figure 1); this indicates that FCM may define VNN2 positivity more
precisely. Eleven (50%) of these 22 VNN21 patients eventually
relapsed, which again indicates that VNN2 expression is an
indicator for resistant disease (Figure 1F). Taken together, pediatric
BCP ALL leukemias with VNN2 expression are associated with
a lower event-free survival and a higher MRD-based risk for relapse.
VNN2 is detected predominantly in MRD HR and MR
patients by prospective FCM
To validate VNN2 in pediatric BCP ALL prospectively, we included
VNN2 in the diagnostic FCM panel of the AIEOP-BFM ALL 2009
study. Positivity was defined as $10% of cells being positive
compared with the internal cross-lineage, CD45bright control
(supplemental Figure 2). In total, 1069 patients were evaluated, of
whom 103 were VNN21, which translates to 10% VNN2 positivity
in BCP ALL (Figure 2A). We confirmed that VNN2 is detected
predominantly in MRD HR and MR ALL patients and at lower
frequency in MRD SR ALL (17%) compared with what has been
reported28 (Table 1). VNN2 is detected across different genetic
subtypes (Figure 2B). It was associated with detection of CD11a,
an integrin implicated in cell adhesion, but not with bilineage acute
leukemia or mixed phenotype acute leukemia status (Figure 2B;
supplemental Table 3). Of note, we detected VNN2 in all leukemias
bearing the translocation t(17;19)(q22;p13) (Figure 1A), which
results in the oncogenic TCF3-HLF transcription factor fusion and
defines a rare, but generally incurable, ALL subtype (,1% of
pediatric ALL).29,30 Having established an international consortium
to study the genomic landscape of this rare subtype,5 we evaluated
18 TCF3-HLF1 ALL samples by FCM and confirmed consistent
positivity for VNN2 in patient samples and in PDXs (Figures 1A, 2C).
VNN2 positivity remained stable when comparing samples taken at
diagnosis and at day 15 from 9 patients with ALL (Figure 2D).
Matched samples from diagnosis and first relapse were available for
22 cases, selected from a cohort of isolated and combined BM
(involvement of extramedullary compartment, ALL-REZ BFM 2002
study) based on sample availability. Two samples were VNN21
at both diagnosis and relapse, whereas 5 cases were positive at
first relapse (Figure 2E). Relapses in VNN21 patients occurred
very early/early compared with VNN22 patients (86% vs 26.6%;
P 5 .02). Taking advantage of our ex vivo drug response profiling
platform,31 we screened 10 VNN21 ALL samples for sensitivity to
standard chemotherapeutic agents of induction therapy. Compar-
ison with 8 samples from ALL samples from the SR group revealed
lower sensitivity of VNN2 ALL to dexamethasone, bortezomib, and
anthracyclines (Figure 2E), further supporting the notion that
VNN21 ALL is associated with chemoresistance.
Because VNN2 defines a human FLHSC compartment18 and
marks human cord blood–derived primitive CD342 HSCs,19 we
evaluated BM and PB samples from healthy adults and children.
VNN2 was readily detectable in HSCs from normal BM, including
HSC subpopulations with very high VNN2 surface expression
(supplemental Figure 3). Intriguingly, VNN2 was not expressed in
mobilized PB HSCs. As expected, VNN2 was highly expressed on
Table 3. Prognostic significance of VNN2 expression in a
multivariable setting (n 5 476)
Group HR LL UL P (x2)
Cox EFS
MRD HR 5.16 2.58 10.32 ,.001
VNN2 2.14 1.28 3.55 .003
SET 2.67 1.19 6.00 .017
WBC $100000 2.01 1.08 3.73 .027
MRD SR 0.74 0.43 1.27 .275
Pred. resp. 0.71 0.33 1.52 .379
ETV6-RUNX1 0.93 0.51 1.70 .812
Cox RFS
VNN2 1.97 1.13 3.44 .016
MRD HR 2.85 1.20 6.80 .018
WBC $100000 2.17 1.12 4.21 .021
SER 2.41 1.01 5.74 .046
MRD SR 0.67 0.37 1.21 .182
ETV6-RUNX1 0.74 0.38 1.45 .379
Pred. resp. 0.81 0.35 1.86 .623
Analysis was performed on 476 samples from the test set from ALL-BFM 2000.
EFS, event-free survival; HR, hazard ratio; LL, lower limit of 95% confidence interval; Pred.
resp, prednisone good responders; RFS, relapse-free survival; SER, slow early responders,
a HR criterium; UL, upper limit of 95% confidence interval; WBC, white blood cell.
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Figure 2. Prospective validation of VNN2 by FCM confirms its association with MRD. (A) FCM evaluation of VNN2 in diagnostic samples from 1069 B-cell ALL
patients enrolled in the AIEOP-BFM 2009 study. (B) Classification of 72 BFM 2009 VNN21 patients based on cytogenetic information and FCM data. Cytogenetic data were
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mature granulocytes and monocytes and weakly expressed on
other lymphocytes. These results support the use of FCM for
VNN2 detection in clinical studies. The prognostic value of VNN2
will require further maturation of the clinical data.
The gene expression signature of VNN2
1
ALL reveals
immune and cell adhesion features, as well as
myeloid characteristics
To obtain a gene expression signature associated with VNN2
expression, we performed a transcriptome analysis of 50 B-cell ALL
(B-ALL) leukemia samples with low to high VNN2 RNA expression
with TCF3-HLF–rearranged, TCF3-PBX1–rearranged, IKZF1plus,
IKZF1deleted, hyperdiploid, hypodiploid, and additional ALL without
known genetic features (so-called B-others) (Figure 3A). After
fitting a linear model using VNN2 as a predictor of gene expression,
we identified a VNN2 signature with 1061 genes that strongly
correlated with VNN2; 549 and 512 genes were positively and
negatively correlated, respectively. This VNN2 signature includes
some of the surface proteins that we detected in HR MRD ALL
by proteomics (Figure 3A). We found an overrepresentation of
features functionally related to cell adhesion, the immune response,
and the JAK-STAT pathway (Figure 3B). By gene-set enrichment
analysis (Figure 3C) and using a different method based on text
mining annotations (Figure 3D; supplemental Table 4), we found an
association between the VNN2 signature and myeloid features and
detected a significant reduction in PAX5 expression, which is in line
with the genomic features of VNN21 TCF3-HLF ALL.5 However,
VNN2 appears to be dispensable for leukemia maintenance and
propagation, because we could generate and serially passage
2 VNN2-knockout samples using clustered regularly interspaced
short palindromic repeats/Cas9 in NSG mice (supplemental
Figure 1D). More studies will be required to carefully evaluate the
impact of VNN2 on sites of leukemia involvement in this PDX model.
VNN21 ALL includes different B-ALL subtypes,
combining inactivation of B-cell developmental
genes, frequent homozygous CDKN2A/B deletions,
and mutations affecting epigenetic regulators
To identify underlying genetic alterations, we applied next-generation
sequencing analysis integrating short and large insert size paired-end
whole-genome and whole-exome sequencing to a discovery cohort
consisting of 22 VNN21, TCF3-HLF2 diagnostic samples (supple-
mental Figure 4). Genomic information from TCF3-HLF1 patients
was available from our previous study.5
Of note, we detected frequent monoallelic deletions of PAX5, al-
most always combined with deletion of CDKN2A/B and sometimes
combined with deletions of IKZF1 (Figure 4). In 1 sample we
detected the PAX5 P80R mutation, in combination with biallelic
deletion of CDKNA/B. We observed mutations affecting IKZF1 in
8 of 22 samples (36%), primarily hemizygous deletions (5/8), but
also homozygous deletions (2/8) and 1 single-nucleotide variant.
Five of the patients (23%) with IKZF1 deletions, all from non-SR
subgroups, fit the definition of IKZF1plus cases, which represent
a new subtype with very poor outcome on the AIEOP-BFM
protocol.8 This frequency of IKZF1 deletions is expected in ALL,32
but IKZF1plus appears to be enriched compared with the 6%
frequency reported previously.8 In addition to TCF3-HLF fusions,
we identified rearrangements of TCF3 with ZNF384, a recur-
rent mutation in ALL,33 as well as with JAK2, which has not
been described previously. We also found a JAK2-BCR fusion,
previously described in BCR-ABL–like ALL.34 Thus, the VNN2
phenotype was detected across different leukemia-initiating
lesions, including IKZF1plus, possibly B-ALLs corresponding to
the recently defined PAX5alt subtype,1 TCF3-rearranged ALL,
and, rarely, BCR-ABL–like subtypes.
As expected in these B-ALL subtypes, we detected frequent gain-
of-function single-nucleotide variants in the Ras pathway, such as
PTPN11, NRAS, and KRAS (Figure 4; supplemental Table 6). In
addition, we noticed frequent mutations in epigenetic regulators in
13 of 22 (60%) VNN21 patients at first diagnosis (Figure 4),
suggesting a marked increase compared with frequencies reported
previously for pediatric B-ALL (12/42 5 30%).35 Interestingly, we
did not find these epigenetic mutations in TCF3-HLF cases.5 To
confirm possible enrichment of epigenetic mutations in MRD MR
ALL, we performed targeted sequencing of the histone-lysine
methyltransferases EZH2, KMT2D, and SETD2, as well as the
lysine demethylase KDM6A, on 185 samples from the retrospective
ALL-BFM-2000 MRD-MR cohort in which we also determined
VNN2 mRNA levels by q-PCR (supplemental Table 7). In this MRD
MR cohort, 15 of 35 (43%) VNN21 patients and 19 of 150 (13%)
VNN22 patients displayed$1 mutation in these 4 genes. Mutations
in this functional class have been reported for a subset of patients
with PAX5alt and PAX5 P80R.1 Taken together, we identify a VNN2
signature that is clearly associated with resistance to chemotherapy
but that is found in different molecular B-ALL subtypes, mostly with
lesions in B-cell developmental genes and, frequently, in genes
affecting epigenetic modification. These features should be in-
cluded in upcoming prospective international trials to evaluate their
contribution to more precise risk stratification in ALL.
Discussion
This study identifies a recurrent VNN2 signature that is associated
with increased resistance to chemotherapy in 10% of BCP ALL
cases across different ALL subtypes, primarily stratified in the MR
and HR groups based on resistance to treatment, as assessed by
Figure 2. (continued) available for 72 of 103 patients identified by FCM. (C) VNN2 expression by FCM identifies TCF3-HLF–rearranged samples. Green dots indicate
TCF3-HLF–rearranged samples (patient and PDX), and pink dots indicate TCF3-PBX1–rearranged PDX samples. Arrows indicate matched patient-PDX sample or matched
xenograft samples at diagnosis-relapse. Asterisks (*) indicate matched diagnosis-relapsed samples. TCF3-HLF rearranged samples scored positive for VNN2 by FCM (.10%).
(D) Analysis of VNN2 in matched samples from 9 patients taken at diagnosis of ALL (day 0) and at day 15 by FCM. (E) Comparison of matched diagnosis (black circles) and
relapse (gray rhombus) pairs indicated conservation of VNN2 positivity; in some cases, an increase in VNN2 from diagnosis to relapse could be observed. FCM was used to
evaluate VNN2 of matched diagnosis and first relapse of 22 patients with ALL. (F) Ex vivo drug response profiling of 10 VNN21 ALL samples (red circles) compared with 8
VNN22 SR cases (blue circles). Patient samples were tested for dexamethasone (DEX), mitoxantrone (MITOX), bortezomib (BORTEZ), vincristine (VINCR), doxorubicin (DOX),
and idarubicin (IDA). **P , .05. BAL, biphenotypic acute leukemia according to EGIL classification; B-ALL, B-cell ALL; dx, diagnosis; FMO, fluorescence-minus-one; IC50,
50% inhibitory concentration; MPAL, mixed phenotype ALL, according to World Health Organization classification23; rz, relapse; SE, standard error.
























































































































































































































































































































































































Figure 3. The signature of VNN21 ALL is enriched with myeloid features and functional annotations related to immune response, interferon signaling, cell
adhesion, and the JAK-STAT pathway. (A) Heat map with 1061 differentially expressed genes showing the transcriptome signature of 50 B-ALL samples ordered by
increasing VNN2 RNA expression (left panel). Using edgeR,48 a linear model was fitted across the dataset of 50 ALL samples using VNN2 expression as predictor of gene
expression. Genes that showed a significant linear relationship with VNN2 expression were selected (false discovery rate [FDR] #0.01). Genes were additionally filtered using
Spearman correlation (FDR #0.04). A total of 549 genes and 512 genes appeared to be positively or negatively correlated with VNN2, respectively. Genes positively
correlated with VNN2 include 3 genes that were identified by proteomics in an independent cohort using CSC technology (right panels). (B) Positively correlated genes were
grouped by pathways using the online tool and database ConsensusPathDB49 (FDR #0.01). The most significantly overrepresented pathways (according to P value) included
the immune system, interferon signaling, b-2 integrin–mediated interactions, and the JAK-STAT signaling pathway. Node size indicates the number of genes contained and the
color refers to significance (P value). Two nodes are connected by a line if they share members. The line width reflects the relative overlap between the nodes, whereas the line
color represents the number of shared members that are also found in the input. (C) Enrichment plot for the myeloid signature obtained after performing gene set enrichment
analysis.50 (D) Components of the VNN21 ALL signature generated using the Genomatix genome analyzer reveal functional annotations related to myeloid cells and their
cellular location (adjusted P # .05; P # .01). Lines between genes indicate a functional association. The line type indicates the evidence level. Dashed lines indicate
a functional association based on cocitation or experimental validation. Solid lines indicate a functional association based on expert curation. Diamonds indicate that a gene
carries a binding site of the associated transcription factor. Arrows indicate that a gene is altered by the associated gene. Curved lines indicate that a gene alters itself on
a transcriptional or protein level. The line type indicates the evidence level. Myeloid_DN, myeloid gene expression signature; NES, normalized enrichment score.
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MRD. Most of the relapses in ALL still occur in the MR group by
MRD.8,36,37 Although patients with more resistant leukemia may
need a different intervention, many patients in the MR group may
benefit instead from a reduction in treatment intensity to minimize
long-term toxicity.
Expression and cell surface display of the glycosylphosphatidylinositol-
anchored surface protein VNN2/GPI-80 is associated with myeloid
features that are not captured by current definitions of bilineage and
mixed immunophenotypes by diagnostic FCM.23 VNN2 itself was
recently identified as a marker of self-renewing human FLHSCs18
and cord blood–derived HSCs.19 In this study, we detected strong
VNN2 expression in subsets of human adult BM HSCs from healthy
individuals, confirming its implication in the very early stages of
hematopoiesis. We also found recurrent surface markers associ-
ated with VNN2, including VNN1 and members of the integrin
and selectin family. Functionally, these proteins are involved in cell
adhesion and processes linked to inflammation. VNN2 has been
implicated in inflammation, contributing to leukocyte adhesion and
migration to inflammatory sites in association with cell surface
integrins.17 It is conceivable that this signature reflects functional
states that are important for interactions with the leukemia
microenvironment and involvement at sanctuary sites. Given the
strong correlation between mRNA and protein levels, VNN2 is
regulated at the transcriptional level. Because of the marked
expression of VNN2 in the normal myeloid compartment, FCM
represents the methodology of choice to detect VNN2 positivity at
the single-cell level on ALL cells.
From a genomics standpoint, we detected a reduction in PAX5
gene dosage in the majority of samples that we tested thus far,
which is reminiscent of our observation in TCF3-HLF1 ALL.5 In our
cohort, events leading to PAX5 loss of function were primarily
monoallelic, which is in contrast with the majority of the samples for
2 recently described entities in ALL, PAX5alt1 and PAX5 P80R,38 in
which both alleles of PAX5 are generally affected. Indeed, VNN2
expression was also detected in the IKZF1plus ALL subtype, which
has been identified based on the combination of IKZF1 deletions
that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or
PAR1 in the absence of ERG deletions, marking a subtype with
poor outcomes in patients with MRD MR ALL or MRD HR ALL.8
Of note, we detected genetic alterations affecting epigenetic
modifiers in 13 of 22 VNN21 ALLs. The methyltransferases EZH2,
KMT2D, and SETD2, as well as the lysine demethylase KDM6A,
were affected recurrently. Similar mutations have been reported in
a subset of PAX5alt and PAX5 P80R B-ALL patients.1 Loss-of-
function mutations in EZH2 have been reported in T-cell ALL and
B-ALL at low frequencies,39-41 as well as in myeloid disorders.42
Moreover, loss-of-function mutations in EZH2 have very recently
been associated with poor outcome in AML.43 MLL2 deficiency
impedes B-cell differentiation and is a driver of lymphoma in vivo.44
Moreover, mutations in SETD2 and KDM6A have been reported
to be enriched in relapsed pediatric B-ALL,45 which suggests that




































































































































































































































Figure 4. Whole-exome and transcriptome sequencing identified frequent
deletions in PAX5, IKZF1, CDKN2A/B and mutations in epigenetic regu-
lators in VNN21 patients. Whole-exome sequencing was performed in 27 VNN21
patient samples (22 diagnosis, 5 relapse), and transcriptome sequencing was per-
formed in 16 VNN21 patient samples (13 diagnosis, 3 relapse). Details about sam-
ple selection are described in supplemental Figure 4. Sample identifiers are shown
Figure 4. (continued) at the bottom of the figure. «V_a» indicates samples at di-
agnosis, and «V_c» indicates samples at relapse. Samples in which transcriptome
sequencing was performed can be identified by an additional «_dx» or «_rz» at the
end of the identifier. dx, diagnosis; rz, relapse.
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KDM6A is crucial in B-cell lymphoma44 and T-cell ALL,46 contrib-
uting to tumorigenesis by deregulation of complexes that control
histone methylation in important regulatory regions.47
Taken together, we have identified a new signature in ALL, whereby
surface expression of VNN2 is associated with increased resis-
tance to induction chemotherapy. Our results support a prospective
evaluation of VNN2 by FCM in the ongoing AIEOP-BFM ALL trial.
We propose to explore the prognostic significance of this marker,
along with more complex genomic information, to improve the
identification of patients who will eventually relapse, in particular those
with IR ALL, the largest risk group, on the current treatment protocol.
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